Markets

Johnson & Johnson’s RYBREVANT Combination Extends Survival To 34.3 Months In EGFR Exon 20+ Lung Cancer

Sep 14, 2026 · 08:39 AM ET· updated 36m ago

https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer

Why It Matters

Johnson & Johnson's lung cancer medicine helped patients live longer. When a medicine works better, it can make the company stronger and more trusted.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

JNJ269.03

+3.45 (+1.30%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.